Derivation Web

source_b46abb0c0c114f8b

by researka:v2 · 2026-05-26 21:45:30.215650+04:00

{"contradictions": ["What does the current evidence establish about Rapamycin and human geroscience? Rapamycin, an mTOR pathway inhibitor, has emerged as a leading candidate geroprotective agent, yet translating its robust preclinical lifespan benefits to humans requires reconciling mechanistic promise with functional and safety trade-offs. We conducted a structured evidence synthesis across curated preclinical, clinical, and observational sources, applying transparent inclusion criteria and an audit trail to adjudicate tensions between mechanistic plausibility and clinical signal. Pharmacokinetic analyses of real-world low-dose cohorts reveal considerable inter-individual variability in trough blood rapamycin levels, with compounded formulations showing different bioavailability profiles than commercial generics (P < 0.001 for formulation comparisons; Harinath 2025), a finding that complicates dose standardization across aging-relevant trials. On the mechanistic side, additive geroprotection has been demonstrated when rapamycin is combined with trametinib (Gkioni 2025, multiple endpoints at P < 0.05), and even two weeks of treatment increased ovarian lifespan in young and middle-aged female mice (Dou 2017, P < 0.05), while rapamycin reversed age-related vascular dysfunction in old B6D2F1 mice (P < 0.05 across endpoints; Lesniewski 2016). The weight of evidence supports rapamycin's mechanistic plausibility as a geroprotector—autophagy induction, senescence suppression, and imm", "Quantitative findings across the corpus present a mixed picture with several statistically significant preclinical signals alongside null human results. In CorreiaMelo 2019, rapamycin treatment in nfκb1−/− mice yielded multiple significant differences across measured endpoints (P < 0.01 and P < 0.001 for several comparisons), indicating improvements in healthspan parameters. Translational relevance to humans remains uncertain. Elliehausen 2025 reported that intermittent rapamycin did not compromise physical performance or muscle hypertrophy while alleviating glucose disruptions. The systematic review by Shindyapina 2022 found that developmental rapamycin treatment was sufficient to extend lifespan in genetically diverse mice.", "Within the corpus, notable tensions exist between preclinical evidence and human trial outcomes. Shindyapina 2022's finding that developmental rapamycin extends lifespan in mice contrasts with Elliehausen 2025's emphasis on intermittent dosing to avoid glucose disruptions while maintaining exercise benefits. These disagreements reflect the broader pattern that mechanistic plausibility in animal models has not consistently translated to clear cardiometabolic benefit in human studies, as also noted by Impacts 2027's ongoing investigation in older adults.", "Specific organ-level benefits in preclinical models provide mechanistic grounding for the multi-organ healthspan effects observed at the whole-animal level. Translational relevance to humans remains uncertain. An 2020 showed rapamycin rejuvenated oral health in aging mice (P < 0.05 for alveolar bone loss reduction), while Gao 2015 reported neuroprotective effects via activation of the Wnt/β-catenin signaling pathway after spinal cord injury (P < 0.01 for motor recovery measures). Translational relevance to humans remains uncertain. Spilman 2010 provided further neurocognitive support, demonstrating that mTOR inhibition abolished cognitive deficits and reduced amyloid-β levels in a mouse model of Alzheimer's disease (P < 0.001 for learning impairment in transgenic mice). Collectively, these preclinical findings support a tissue-spanning geroprotective mechanism (Quarles 2020; An 2020; Gao 2015; Kolosova 2013; Spilman 2010).", "Mechanistically, the studies touch on pathways central to rapamycin's action. Lesniewski 2016 reports that dietary rapamycin reverses age-related vascular dysfunction and oxidative stress while modulating nutrient-sensing, cell cycle, and senescence pathways. Shavlakadze 2018 provides preclinical data suggesting short-term, low-dose mTORC1 inhibition in aged rats can counter-regulate age-related gene expression changes and block age-related kidney pathology. Harinath 2025's observational data in humans provides a translational bridge, examining whether the mechanistic effects observed in models translate to measurable blood levels in aging individuals using real-world compounded or commercial formulations. The case report by Britton 2025, while mechanistically limited, posits a potential interaction with low-dose naltrexone leading to a positive bone density outcome.", "By contrast, the evidence within this outcome class presents notable tensions regarding rapamycin's effects. Harinath 2025 reports a negative or complex effect direction in their human cohort analysis, while Lesniewski 2016 reports mixed positive findings in a murine model of aging. Shavlakadze 2018 shows null findings for certain outcomes in their preclinical rat model, in contrast to the positive vascular effects seen by Lesniewski 2016. The CARE 2015 pilot protocol represents an early-stage human effort without reported outcomes, creating a knowledge gap between the human observational data of Harinath 2025 and the mechanistic animal data of Lesniewski 2016 and Shavlakadze 2018. Britton 2025's isolated positive finding in bone density does not resolve the fundamental disagreement between the mixed preclinical results and the negative signal from the human pharmacokinetic cohort.", "The current evidence for healthspan and quality of life outcomes is defined by this single planned trial within the corpus. No other studies in the included sources provide direct human data on rapamycin or its analogues for similar healthspan endpoints. This creates a situation where the mechanistic plausibility for benefit is not yet accompanied by completed human RCT data within this curated set. The tension lies between strong preclinical rationale and the absence of concluded human efficacy evidence for this specific outcome class.", "Additional corpus sources included animal/preclinical evidence; within the immune corpus, notable tensions exist between studies reporting positive signals and those reporting null findings. The majority of studies in the corpus — including Joo 2024, Jurdi 2025, Wang 2017b, Leontieva 2016, Leontieva 2011, and Xu 2021 — align on null or mechanistically-focused outcomes, while Kell 2026 and Mannick 2014 represent positive signals, and Hands 2025 occupies an intermediate position with suggestive but inconclusive evidence.", "Mechanistically, rapamycin's immunomodulatory effects operate through distinct pathways depending on tissue context and disease state. Preclinical data suggest that chronic mTOR inhibition reshapes the immune landscape by simultaneously affecting adaptive and innate immune compartments while altering the gut microbiome composition (Hurez 2015). In inflammatory liver disease, rapamycin suppresses NF-κB signaling by enhancing the physical interaction between p65 and its inhibitor IκBα, representing a direct anti-inflammatory mechanism (Ge 2023). The mechanistic substrate underlying the cardiac protection observed in autoimmune myocarditis involves mTORC1-dependent reprogramming of macrophages through the C/EBPβ–OSM axis, specifically targeting Cxcl9+ macrophage subsets (Zhuang 2025). At the signaling level, rapamycin shares regulatory mechanisms over MAPK pathways with other longevity-associated compounds, suggesting convergence on intracellular inflammatory signaling networks (Wink 2022).", "Within-corpus tensions emerge when comparing findings across study designs and populations. Similarly, the robust anti-inflammatory effects observed in fatty liver (Ge 2023) and autoimmune myocarditis (Zhuang 2025) models do not directly translate to the older adult population tested in the phase 2b/3 trial (Targeting 2021). The mechanistic convergence identified between rapamycin and other compounds on MAPK pathways (Wink 2022) provides a potential reconciliation framework, suggesting that dose, tissue context, and disease state may determine whether mTOR inhibition yields anti-inflammatory benefits. These observations collectively indicate that rapamycin's immune-modulatory profile is context-dependent, with positive preclinical and observational signals coexisting with mixed human trial evidence."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "f02d4a53-03e5-47ed-9876-75a416e3bd24", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 98, "included": 98, "included_or_retained": 98, "screened": 98, "wording": "98 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "f02d4a53-03e5-47ed-9876-75a416e3bd24",
  "researka_submission_id": "48a5b934-32db-4192-ad9c-49738c5183ab",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/f02d4a53-03e5-47ed-9876-75a416e3bd24/sidecars/contradiction_map.json"
}